175 related articles for article (PubMed ID: 32083417)
1. A systematic review of imaging-guided metastasis-directed therapy for oligorecurrent prostate cancer: revolution or devolution?
Albisinni S; Van Damme J; Aoun F; Bou Kheir G; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2020 Jun; 72(3):279-291. PubMed ID: 32083417
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of contemporary management of oligometastatic prostate cancer: fighting a challenge or tilting at windmills?
Slaoui A; Albisinni S; Aoun F; Assenmacher G; Al Hajj Obeid W; Diamand R; Regragui S; Touzani A; Bakar A; Mesfioui A; Karmouni T; Ameur A; Elkhader K; Koutani A; Ibnattya A; Roumeguere T; Peltier A
World J Urol; 2019 Nov; 37(11):2343-2353. PubMed ID: 30706122
[TBL] [Abstract][Full Text] [Related]
3. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
[TBL] [Abstract][Full Text] [Related]
4. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
5. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature.
Ost P; Bossi A; Decaestecker K; De Meerleer G; Giannarini G; Karnes RJ; Roach M; Briganti A
Eur Urol; 2015 May; 67(5):852-63. PubMed ID: 25240974
[TBL] [Abstract][Full Text] [Related]
6. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.
Albisinni S; Aoun F; Marcelis Q; Jungels C; Al-Hajj Obeid W; Zanaty M; Tubaro A; Roumeguere T; De Nunzio C
Minerva Urol Nefrol; 2018 Aug; 70(4):347-360. PubMed ID: 29388415
[TBL] [Abstract][Full Text] [Related]
7. Metastasis-directed therapy and prostate-targeted therapy in oligometastatic prostate cancer: a systematic review.
Miura N; Pradere B; Mori K; Mostafaei H; Quhal F; Misrai V; D'Andrea D; Albisinni S; Papalia R; Saika T; Scarpa RM; Shariat SF; Esperto F
Minerva Urol Nefrol; 2020 Oct; 72(5):531-542. PubMed ID: 32550632
[TBL] [Abstract][Full Text] [Related]
8. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
9. Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review.
de Barros HA; van Beurden I; Droghetti M; Wilthagen EA; Özman O; Bergman AM; Aluwini S; van Moorselaar RJA; Donswijk ML; van Leeuwen PJ; van der Poel HG
Eur Urol Oncol; 2023 Feb; 6(1):16-27. PubMed ID: 36372736
[TBL] [Abstract][Full Text] [Related]
10. Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials.
Connor MJ; Smith A; Miah S; Shah TT; Winkler M; Khoo V; Ahmed HU
Eur Urol Oncol; 2020 Oct; 3(5):582-593. PubMed ID: 32891600
[TBL] [Abstract][Full Text] [Related]
11.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
12. Radiotherapy as metastasis-directed therapy for oligometastatic prostate cancer.
De Bleser E; Tran PT; Ost P
Curr Opin Urol; 2017 Nov; 27(6):587-595. PubMed ID: 28816714
[TBL] [Abstract][Full Text] [Related]
13. [Oligorecurrent prostate cancer: current management and perspectives].
Loubersac T; Guimas V; Rio E; Libois V; Rigaud J; Supiot S
Bull Cancer; 2020 Jun; 107(5S):S35-S40. PubMed ID: 32620205
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy.
Devos G; Berghen C; Van Eecke H; Stichele AV; Van Poppel H; Goffin K; Mai C; De Wever L; Albersen M; Everaerts W; De Meerleer G; Joniau S
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823690
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
[TBL] [Abstract][Full Text] [Related]
17. Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: an analysis of clinical trials registries.
De Bruycker A; Tran PT; Achtman AH; Ost P;
World J Urol; 2021 Feb; 39(2):317-326. PubMed ID: 31955223
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive prostatectomy: what is the evidence? A systematic review.
Albisinni S; Aoun F; Diamand R; Al-Hajj Obeid W; Porpiglia F; Roumeguère T; De Nunzio C
Minerva Urol Nefrol; 2019 Feb; 71(1):1-8. PubMed ID: 30547907
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
20. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
